Doctor of Medicine, Doctoral Supervisor, Chief Physician, Professor

Former Director of the Department of Gastroenterology and Intervention, Xijing Hospital of the Fourth Military Medical University

Leader of Cardiovascular Intervention Group in National Digestive Disease Clinical Medicine Research of Xijing Hospital

APPLE Council Member, Asia Pacific Primary Liver Cancer Council

Vice Chairman of Intervention Professional Committee of Chinese Research Hospital Association

Member of the Standing Committee of the Interventional Physician Branch of the Chinese Medical Doctor Association and Deputy Chairman of the Interventional Oncology Committee

Vice Chairman of the Chinese Society of Gerontology, Geriatrics Branch

Member of the Standing Committee of the Liver Cancer Professional Committee of the Chinese Anti-Cancer Association

Deputy Leader of the Collaborative Group of Digestive Minimally Invasive and Intervention, Chinese Society of Gastroenterology

Deputy Leader of the Interventional Therapy Group of the Liver Cancer Diagnosis and Treatment Standardization Expert Group of the Health and Family Planning Commission

Vice Chairman of the Interventional Radiology Branch of Shaanxi Medical Association

As the first person in charge, it has undertaken/completed more than 10 key international cooperation projects of the National Science and Technology Fund, 863 sub-projects, and national "Eleventh Five-Year" supporting projects. Ranked nineteenth in the TOP 100 academic influence rankings in the field of liver diseases in China in 2021, and sixth in the TOP 100 academic influence rankings in the field of digestive diseases in China in 2020. Won the first prize of 2017 Military Science and Technology Progress Award as the first complete person, and won the 2016 National Science and Technology Progress Award Innovation Team Award as a main member, and won the title of Excellent Demeanor of the Second National Famous Doctors Ceremony in 2018, 2011 From 2012 to 2018, he was named Top10dr in the "Top 100 Chinese Medical Doctors" for eight consecutive years. The editor-in-chief participated in the editing of 3 monographs, instructed or counseled 31 masters, 11 doctors, 1 postdoctoral fellow, and 2 researchers.

He has studied in Kanazawa University in Japan and the University of Hong Kong. Mainly engaged in the interventional treatment and clinical research of digestive system diseases such as hepatobiliary and pancreatic tumors, portal hypertension and liver vascular disease (Budd-Chiari syndrome, portal thrombosis and cavernous degeneration, idiopathic portal hypertension, etc.). Participated in more than ten international multi-center liver cancer targeted/immune and/or interventional treatment clinical trials; designed and initiated more than ten domestic multi-center clinical trials led by the team. Since 2011, many research results on portal hypertension and liver cancer have been published as the first or corresponding author in Nat Rev Gastro Hepatol, Ann Oncol, J Hepatol, Gut, Gastroenterology, Lancet Gastro Hepatol, Hepatology, Clin Cancer Res, Radiology, International authoritative magazines such as Am J Gastroenterol have published 150 SCI papers, with the highest single paper being 46.8, of which 8 papers and 11 papers with more than 20 points and 10-20 points respectively. The relevant results were written into 8 international guidelines (2014-2021), including the American Society of Liver Diseases, the European Society of Liver Diseases, and the British Society of Gastroenterology. Published 1 paper each in Lancet as a senior author and a member of the joint board of directors (2017 and 2018). For five consecutive years, he has been invited to give keynote speeches at international academic conferences such as the European Annual Meeting of Liver Diseases (2016-2020), the American Annual Meeting of Liver Diseases, the Asia-Pacific Annual Meeting of Liver Diseases, and the World Congress of Gastroenterology.